Healthcare company NasVax Ltd. (TASE: NSVX) said today that it has received authorization for a patent in the US. The patent covers oral administration of its anti-CD3 antibody.
The patent, titled "Methods of modulating immunity', covers the antibody's use (administered orally) against various inflammatory and autoimmune diseases, such as diabetes, psoriasis, multiple sclerosis, lupus, graft-versus-host disease, and several others.
Nasvax has a licensing deal with Hadasit - the Technology Transfer Company of Hadassah Medical Organization for the research, development, and marketing of immunotherapy treatment using the antibody.
Nasvax shares rose 4.4% by early afternoon.
Published by Globes [online], Israel business news - www.globes-online.com - on October 5, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010